News

New phase 3 trial tests rhNGF eye drops for persistent corneal epithelial defects, aiming for full healing and a first approved PCED therapy.

Alkeus Pharmaceuticals has dosed the first participant in the phase 3 NORTHSTAR trial of oral gildeuretinol for Stargardt disease, a condition with no approved treatments.

Finding satisfaction in ocular research—considerations about AI and enhanced datasets.

Examining the physiologic limits can help identify when its usage may be ineffective

Meeting founder and co-chair Arshad M. Khanani, MD, MA, FASRS, shares what attendees can expect during this year's program, opening the evening of June 12 and running through June 13 in Las Vegas, Nevada.

A newly developed diagnostic system, CaptureTumor (CaT), driven by artificial intelligence (AI) and designed specifically for smartphone deployment, achieved diagnostic accuracy comparable to that of a specialist-graded slit-lamp evaluation” for detecting rare ocular surface malignancies.

Understanding the different expectations between patients with these conditions is key to choosing the appropriate refractive surgery.

LENZ Therapeutics licenses FDA-approved presbyopia drop to Everest Medicines for Greater China; NDA under review by NMPA with approval anticipated in Q1 2027

The FDA has approved ranibizumab-hkdz (Ranluspec; Lupin Limited) as an interchangeable biosimilar for wet AMD, DME, DR, RVO, and mCNV.

A propensity-matched retrospective analysis of more than 920,000 adults finds a 30% higher risk of incident uveitis following human papillomavirus infection.

Guidance includes building on existing science, reducing redundant testing, and accelerating treatments for rare and life-threatening diseases

NYU Langone’s Jordan Mandell, MD, and Ariana Levin, MD, sit down with UCLA’s Anne Coleman, MD, to discuss her recent study on cardiovascular risk scores and their association with glaucoma, AMD, and other ocular diseases.

Researchers report pseudophakic patients implanted with a peripheral vision IOL detected roadway hazards significantly faster than those receiving a standard monofocal lens.

The company confirmed it does not plan to submit a New Drug Application (NDA) to the US Food and Drug Administration (FDA)

Samsung Bioepis launched Opuviz, an aflibercept biosimilar, in Europe for wet AMD, DME, retinal vein occlusion, and myopic CNV.

The topical synthetic peptide receives orphan drug and fast track status and enters phase 2 as a first-in-class treatment for a rare degenerative corneal disease.

Samsung Bioepis launched Opuviz, an aflibercept biosimilar, in Europe for wet AMD, DME, retinal vein occlusion, and myopic CNV.

The study, led by researchers at Keio University School of Medicine, measured near add power in 6258 patients aged 40 to 79.

Andrew G. Lee, MD, and Drew Carey, MD, discuss recurrence of papilledema after discontinuation of GLP-1 receptor agonists and the implications for monitoring patients with idiopathic intracranial hypertension.

Two cases illustrate how recognizing and treating Demodex can change surgical outcomes and resolve chronic dry eye disease.

A pilot study shows that analyzing how the cornea moves under air-puff stimulation may improve early keratoconus detection.

The resubmission follows a successful appeal by the company with the Office of New Drugs (OND).

Genetic testing transforms inherited eye disease care, but expert interpretation matters—learn why false negatives and new gene therapies reshape retina practice.

Researchers from Johnson & Johnson Vision and Aier Eye Hospital present 24-month prospective data showing that Chinese children wearing Abiliti™ 1-Day contact lenses experienced approximately half the axial elongation and myopia progression of a matched spectacle-wearing control group.

Knowing pregnancy-related risks enhances patient safety.

SOL-1 results show intravitreal axitinib hydrogel delivered superior vision maintenance and anatomic outcomes through 52 weeks.

Sharon Fekrat, MD, FACS, FASRS, reviews the science behind dopamine signaling in the retina and its potential role in the progression of age-related macular degeneration.

Dimitra Skondra, MD, PhD, FASRS, shares her perspective on the evolving treatment landscape for dry age-related macular degeneration and the key questions facing the field.